AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$SKYH

Sky Harbour (SKYH) Q3 2026 Earnings Call Transcript

Sky Harbour (SKYH) reported Q3 2026 revenues up 45% YoY and 7% sequentially, driven by new campus openings and higher occupancy. Operating expenses rose due to new hires and lease accruals. Cash flow dipped slightly due to a one-time payment. Subsidiary Sky Harbour Capital saw revenues increase 87% YoY and 13% sequentially, with cash flow from operations at $3.2M. The company expects margin expansion as new campuses stabilize and occupancy increases.

Original reporting
finance.yahoo.com
Published Nov 11, 2026, 4:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 4:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Sky Harbour (SKYH) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SKYHNeutralMed
01

Why it matters

Earnings release provides the first detailed financial metrics for Q3 2026, offering fresh data for valuation models.

02

Market read

The earnings call delivers new quantitative insight into Sky Harbour's growth trajectory, influencing short‑term price action and sector sentiment.

03

What to watch

Cash flow from operations turned positive for 12 quarters; debt service coverage is strong, which may support the stock.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Sky Harbour provides airport hangar leasing and construction services, recently expanding its campus footprint across tier‑1 airports.

Company-level read

Ticker impact

$SKYHNeutralHigh confidence
Context

Q3 2026 earnings call disclosed 45% YoY revenue growth, operating expense increase, and a negative adjusted EBITDA of ~$5M.

Expected impact

potential modest upside as investors price in margin expansion and revenue growth, tempered by current expense drag

Evidence & confidence

Revenue growth is strong, but negative EBITDA and rising expenses create uncertainty; traders may look for short‑term positioning around the earnings reaction.

Market effects

Sector

Highlights growth potential in airport‑hangar leasing sector; may boost peer valuations if margin expansion materializes.

Regional

U.S. aviation real‑estate niche sees increased investor interest.

Global

Limited to niche infrastructure investors; no broad market effect.

Counterpoint

What could challenge this read

Higher operating expenses and negative EBITDA could signal overextension; caution on upside.

Key entities

  • Company
    Sky Harbour

    U.S. listed provider of airport hangar leasing and construction.

  • Executive
    Tal Keinan

    CEO discussing growth strategy and campus development.

Read at source← All news

Also covered by

1 outlet

Related articles

$SKYHMed

What Sky Harbour Group (SKYH) Said on Its Q3 Earnings Call

Sky Harbour Group (SKYH) reported Q3 earnings, highlighting increased operating expenses and slightly negative operating cash flow due to a $1M interest payment. Assets under construction reached $439M, a record. The Obligated Group saw 87% revenue growth and $3.2M in operating cash flow. The company expects revenue growth from Addison phase II and focuses on 'tier 1' airport acquisitions. Leasing remains a challenge, with 826,000 sq ft to fill in 2027.

finance.yahoo.com
$SKYHMed

Sky Harbour Announces Record Q3 Results and Updates on Leasing, Construction, New Ground Leases and Other Activities Guidance Revised for Year End 2026

Sky Harbour Group Corp (SKYH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sky Harbour Announces Record Q3 Results and Updates on Leasing, Construction, New Ground Leases and Other Activities Guidance Revised for Year End 2026 WEST HARRISON, N.Y.--( BUSINESS WIRE )--Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”

SEC EDGAR 8-K
$SKYHMed

Sky Harbour Targets EBITDA Inflection as Private Hangar Network Expands

Sky Harbour Group (NYSE:SKYH) expects to achieve EBITDA positivity by year-end, driven by its expanding network of private hangar campuses. The company operates eight campuses and has 23 ground leases, with four under construction. It aims to maintain development costs around $300 per square foot. Sky Harbour's debt includes a 2021 issuance at 4.18% and a 4.73% construction facility with JPMorgan. Lease rates at Miami Opa-locka averaged $41 per square foot in phase one and $51 in phase two.

finance.yahoo.com
$SKYHMedAI 8/10

Sky Harbour announces $40 million equity financing deal

Sky Harbour Group (SKYH) entered a stock purchase agreement for a registered direct offering of 4,000,000 Class A common shares at $10.00 each, closing Aug. 12, 2026, for $40 million gross proceeds for general corporate purposes. A 90-day lock-up was agreed. Boston Omaha arranged a concurrent secondary sale of 360,000 shares at $10.00, expected to close Aug. 14, 2026.

theglobeandmail.com
$SKYHMed

Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026

Sky Harbour Group Corp (SKYH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026 WEST HARRISON, N.Y.--( BUSINESS WIRE )--Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation

SEC EDGAR 8-K
$SKYHMedAI 8/10

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Skyhawk Therapeutics reported 12-month cUHDRS subcomponent results from its Phase 1/2 trial of oral Huntington’s disease candidate SKY-0515. Mean changes vs expected worsening (from Enroll-HD propensity-weighted analyses) were favorable for TFC (+0.07 vs -0.87), TMS (-2.00 vs 2.21), SDMT (-0.19 vs -1.78), and SWRT (+3.44 vs -3.13). CGI/PGI showed no assessed worsening and 65% of participants/50% of clinicians reported improvement; mHTT blood reductions up to 69% and PMS1 mRNA up to 26%.

finanznachrichten.de